WELCOME TO THE MAQC SOCIETY
Please read the following:
Based on recent reports from the World Health Organization (WHO) and the American Centers for Disease Control and Prevention (CDC), the MAQC Society is announcing the postponement of the MAQC Society 2020 Meeting (originally April 8-April 10) at SAS Institute in Cary, NC. The new date is April 27-30, 2021 at the SAS Institute (same location).
The objective of the MAQC Society is to communicate, promote, and advance reproducible science principles and quality control for analysis of the massive data generated from the existing and emerging technologies in solving biological, health, and medical problems. Thus, the goals of the Society are to (1) advocate and facilitate the development and application of quality control practice and standard analysis protocols of bioinformatics and biostatistics for enhanced reproducibility across multiple experiments, laboratories, and data analysis methods, and (2) advance our understanding and best practices in the analysis of massive data from emerging technologies applied in drug development, clinical application, and safety/risk assessment.
Due to the international COVID -19 pandemic, the MAQC Society rescheduled the MAQC Society 2020 Meeting at SAS Institute in Cary, NC for April 28-30, 2021 at the SAS Institute (same location). A sister organization, MCBIOS, will be planning to meet April 26-28, 2021.
MAQC SOCIETY AT A GLANCE
A Bit of Background
Historically, the MAQC/SEQC has been a US FDA‐led community-wide consortium effort to address issues relating to the application of constantly evolving high‐throughput genomics technologies to either assess safety and efficacy of FDA regulated products or their safe and effective use in clinical applications as in vitro diagnostic devices. The MAQC consortium completed three projects between 2005 ‐2014 (namely MAQC I, II and III), resulting in ~30 publications and one third of which were published in Nature Biotechnology. Furthermore, two of these papers were among the most cited in Nature Biotechnology in the last 20 years. The MAQC Society is currently completely work on SEQC2 resulting in additional publications in Nature Biotechnology and other journals regarding best practices in DNA analysis. Additional information about MAQC Consortium projects is available here. The success enjoyed by consortium members led us to create a new society whose mission is to promote reproducible scientific research, especially research that involves analysis of massive data sets but which include additional areas benefiting human health: medical and pathology imaging, proteomics and other -omics, large health-related studies and databases, etc.
Recent Activities and Meetings
MAQC Workshops, Key Publications, and Society Meetings
Kohn's Second Law: An experiment is reproducible until another laboratory tries to repeat it
We should be asking, 'How much of an effect is there?', not 'Is there an effect?'”
MAQC Society Board of Directors
A Board of Directors is chartered to develop the Society and oversee the Society’s activities. Specifically, the Board is dedicated to building and strengthening the reproducible science practice by (1) engaging scientists in academia, industry, and government, (2) fostering collaboration and harmonization of education, research tools, and new technologies, and (3) building the global-scientific infrastructure needed to advance and promote reproducible science.
L-R Back Row: Dr. Weida Tong, Dr. Joaquin Dopazo, Dr. Cesare Furlanello, Dr. Leming Shi, Dr. Matthias Fischer, Dr. Christopher Mason, Dr. Benjamin Haibe-Kains, Dr. Russell Wolfinger, Dr. Wendell Jones
L-R Front Row: Dr. Wenjun Bao, Dr. Rebecca Kusko, Dr. Shraddha Thakkar, Dr. Susanna Sansone